A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

NCT01955603 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammation
Rheumatoid Arthritis

Interventions

DRUG: NNC0215-0384
DRUG: placebo

Sponsor

Novo Nordisk A/S